The prostate cancer market is expected to experience a moderate growth between 2016 and 2026. The main drivers of growth will be the expected label expansion of secondgeneration hormonal agents into hormonesensitive disease and nonmetastatic castration resistant prostate cancer nmCRPC, and the launch and uptake of nine new premiumpriced therapies.
Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/pharmapointprostate-cancer-drug-forecast-market-91
Until now, the hormone sensitive setting has been dominated by the use of cheap firstgeneration hormonal agents, with the use of premiumpriced secondgeneration hormonal agents Xtandi and Zytiga limited to metastatic CRPC. The prostate cancer competitive landscape is going to experience a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities. GlobalData expects these biomarkerdriven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm.
Scope
- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to
- Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/pharmapointprostate-cancer-drug-forecast-market-91
No comments:
Post a Comment